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Background: Decision making regarding air pollution can be better informed if air quality impacts 
are traced back to individual emission sources. Adjoint or backward sensitivity analy sis is a model-
ing tool that can achieve this goal by allowing for quantification of how emissions from sources in 
different locations influence human health metrics.
oBjectives: We attributed short-term mortality (valuated as an overall “health bene fit”) in Canada 
and the United States to anthropogenic nitrogen oxides (NOx) and volatile organic compound 
(VOC) emissions across North America.
Methods: We integrated epidemiological data derived from Canadian and U.S. time-series studies 
with the adjoint of an air quality model and also estimated influences of anthropogenic emissions at 
each location on nationwide health bene fits.
results: We found significant spatiotemporal variability in estimated health bene fit influences of 
NOx and VOC emission reductions on Canada and U.S. mortality. The largest estimated influences 
on Canada (up to $250,000/day) were from emissions originating in the Quebec City–Windsor 
Corridor, where population centers are concentrated. Estimated influences on the United States 
tend to be widespread and more substantial owing to both larger emissions and larger populations. 
The health bene fit influences calculated using 24-hr average ozone (O3) concentrations are lower in 
magnitude than estimates calculated using daily 1-hr maximum O3 concentrations.
conclusions: Source specificity of the adjoint approach provides valuable information for guiding 
air quality decision making. Adjoint results suggest that the health bene fits of reducing NOx and 
VOC emissions are substantial and highly variable across North America.
key words: adjoint sensitivity analy sis, health bene fits, nitrogen dioxide, ozone mortality, source 
attribution. Environ Health Perspect 121:572–579 (2013). http://dx.doi.org/10.1289/ehp.1205561 
[Online 22 February 2013]
Acute and chronic exposure to ambient air 
pollution has been directly linked with adverse 
human health effects, resulting in substan-
tial social and economic burdens worldwide. 
Several time-series and cohort studies con-
ducted over the past few decades have exam-
ined the effects of particulate matter (PM) and 
gas-phase pollutants on short and long-term 
mortality and morbidity. In application, the 
results of such studies have been linked with 
air quality modeling to estimate the global 
burden of air pollution (Anenberg et al. 2010; 
Brauer et al. 2012) and the health impacts of 
intercontinental pollutant transport (Anenberg 
et al. 2009) and to evaluate control measures 
(Tagaris et al. 2010; West et al. 2006).
Ozone (O3) is one of the major photo-
chemical oxidants in ambient air whose short-
term health effects have been widely researched 
(e.g., Bell et al. 2005; Burnett et al. 1997; 
Katsouyanni et al. 2009). In a U.S. multi-
city study, Bell et al. (2004) estimated that a 
10-ppb increase in 24-hr average O3 concen-
tration was associated with a 0.52% increase 
in all-cause mortality. Subsequently, Ito et al. 
(2005) conducted a meta-analy sis of single-
city time-series studies worldwide and found a 
slightly lower estimate of 0.39% for a 10-ppb 
change in 1-hr maximum O3 concentration. 
In a study of 12 major Canadian cities, Burnett 
et al. (2004) associated a 30.6-ppb change in 
2-day moving average O3 concentration with 
a 2.74% change in non accidental mortality. 
More recent cohort studies on the long-term 
effects of O3 (e.g., Jerrett et al. 2009) suggest 
that chronic O3 exposure may have a stronger 
influence on mortality as well as the potential 
to afflict substantially larger societal costs.
Unlike O3, there is a lack of consensus 
concerning the association between nitrogen 
dioxide (NO2) and short-term mortality, due 
in part to a scarcity of epidemiological evi-
dence (e.g., Latza et al. 2009; Stieb et al. 2008). 
However, in a Canadian study, Burnett et al. 
(2004) found that a 22.4-ppb increase in 3-day 
moving average NO2 concentrations was asso-
ciated with a 2.31% increase in non accidental 
mortality. This association was further exam-
ined by Brook et al. (2007), who concluded 
that NO2 is the best single indicator of species 
in the ambient pollution mixture whose human 
health effects are not yet fully understood.
Quantification of health effects can be 
extended to emissions as part of bene fit–cost 
analyses with the use of chemical transport 
models (CTMs) that relate emission rates to 
ambient concentrations of pollutants (e.g., 
Anenberg et al. 2010; West et al. 2006). 
Model-based studies have traditionally used a 
scenario-based approach that aims to quantify 
health effects that would result if emissions 
from all sources were reduced uniformly or 
based on a prescribed scenario. Such studies 
are beneficial in assessing the spatiotemporal 
distribution of health bene fits resulting from 
prescribed changes in model inputs, but can-
not feasibly quantify distinctions between 
health bene fits related to emission reductions 
from sources in different locations and times.
The quantified relationship between 
CTM-based model outputs and inputs is 
referred to as sensitivity analy sis in the context 
of this work. Sensitivity information relates 
changes in emissions coming from sources 
[e.g., nitrogen oxides (NOx) emissions from 
motor vehicles or a power plant] to concen-
trations seen at receptors (e.g., health effects 
related to O3 exposure in a city) and thus 
estimates how much influence a source has 
on a receptor. These influences can be attrib-
uted to changes in emissions for a group of 
sources altogether (e.g., the transportation 
sector), as in previous studies, or instead to 
emissions coming from each source individu-
ally, yielding source- specific information. In 
a bene fit–cost analy sis framework, it is bene-
ficial to know the marginal influences of 
emissions from different source locations on 
health effects. This kind of source-specific 
information can be achieved using adjoint or 
backward sensitivity analy sis in CTMs. In this 
approach, influences on receptors are traced 
back to individual sources at all locations in 
preceding times (hence the term backward).
Here, we present a proof-of-concept study 
for integrating health bene fit assessment  models 
and epidemiological data with the adjoint of 
CTMs (the tool used to conduct adjoint sen-
sitivity analy sis) by forming a direct linkage 
between health effects at a national scale and 
emission sources at each location. We apply 
our methodology to estimate the response of 
national short-term mortality (valuated as an 
overall “health bene fit”) in Canada and the 
United States from short-term exposure to O3 
(and NO2 in Canada) to emission reductions 
in each location across North America.
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Methods
Adjoint sensitivity analy sis. Adjoint sensitivity 
analy sis, within the context of this work, refers 
to the estimation of influences coming from 
emissions at individual source locations on 
short-term O3 mortality aggregated across all 
receptors. The difference between the adjoint 
approach and more conventional methods for 
sensitivity estimation is one of perspective and 
lies in the direction in which sensitivity infor-
mation evolves through the model in time and 
space. Conventional methods for sensitivity 
analy sis track influences of a source, or a group 
of sources (e.g., all power plants), forward in 
time and space to all receptors (e.g., Canada 
and the United States), and are therefore 
referred to as “forward methods.” One such 
approach is the brute-force method in which 
emission inputs to CTMs are changed in the 
model to estimate the resultant distribution of 
concentrations across all receptor locations and 
times. With this method, it is a prohibitively 
costly undertaking to estimate influences of 
individual sources because each source requires 
its emissions to be perturbed separately. A par-
ticular type of brute-force method, known 
as zero-out sensitivity analy sis, requires emis-
sions from a particular source be set to zero 
on the premise that removing a source will 
reveal its overall influence. In contrast, adjoint 
sensitivity analy sis is a “backward method” 
that calculates influences of each source loca-
tion on a single receptor or an ensemble of 
receptors. A single adjoint simulation provides 
sensitivities of a model output with respect to 
inputs across all locations and times (e.g., how 
O3-related mortality in Canada changes as a 
result of a change in emissions in any loca-
tion) without requiring any perturbations to 
be made to model inputs themselves.
Detailed explanation of adjoint sensitivity 
analy sis in air quality modeling can be found 
elsewhere (Hakami et al. 2007; Henze et al. 
2007; Sandu et al. 2005); here, we provide a 
descriptive overview. As mentioned above, the 
adjoint method can provide information about 
influences of location-specific sources on a 
function such as nation wide mortality that 
depends on concentrations across many recep-
tor locations. This concentration-dependent 
function is commonly called the adjoint cost 
function. We define the adjoint cost function 
as the monetary value of mortality (M) result-
ing from short-term exposure to O3 (and NO2 
in Canada). We use epidemiological concen-
tration response functions, population data, 
and recorded baseline mortality rates to estab-
lish a concentration-based adjoint cost func-
tion. Our adjoint sensitivity results, therefore, 
estimate influences from emissions in different 
source locations and for different species on 
nationwide mortality metrics.
Linkage between epidemiological models 
and adjoint calculations is established through 
the appropriate definition of the adjoint cost 
function. A change in mortality valuation 
(∆M) associated with a change in pollutant 
concentration (∆C) is often given by
 ∆M = M0 × P × VSL(1 – e–β∆C ), [1]
where M0 is the baseline non accidental mor-
tality rate, P is the population, VSL is the 
value of statistical life (VSL), and β is the 
concentration– response factor based on epi-
demiological models. VSL is the most com-
mon mortality valuation metric and is a 
measure of an individual’s willingness to pay 
to reduce their probability of death (Alberini 
et al. 2006). Studies that have quantified the 
health bene fits of air pollution reduction have 
often concluded that mortality reduction is 
the largest contributor (Hubbell et al. 2005).
Adjoint sensitivity calculations are driven 
by the adjoint forcing term (φ) in the same 
fashion that concentrations are driven by 
emissions in CTMs. By this analogy, adjoint 
forcing terms can be regarded as “sources of 
influence” in the same way that emissions are 
sources for concentrations. The adjoint forc-
ing term is the local, marginal influence of a 
change in concentration (C) on the adjoint 
cost function (φ = ∂M ⁄ ∂C ≈ ΔM ⁄ΔC). The 
linearized form of Equation 1 results in the 
approximation of the adjoint forcing term:
φ = ∂M ⁄ ∂C ≈ ΔM ⁄ΔC ≈ M0 × P × VSL × β. [2]
Because β is often a small value, the resulting 
error from this linearization is negligible for 
all practical purposes. As Equation 2 suggests, 
adjoint forcing terms, acting as the sources of 
influence, increase with the size of population. 
If only mortality valuation due to O3 expo-
sure is considered, the forcing term applied 
would only include a concentration response 
factor for O3, but because O3 is influenced 
by other species in various locations through 
atmospheric chemistry and transport, emis-
sions of other species [e.g., NOx and volatile 
organic compounds (VOCs)] are linked to 
O3-related mortality in CTMs.
Health outcome valuation. Our estima-
tion of mortality valuation for Canada is 
based on O3 and NO2 short-term mortality. 
The required Canadian data for Equation 2 
are extracted from the Air Quality Benefits 
Assessment Tool (AQBAT) developed by 
Health Canada (Judek et al. 2006), which 
considers O3 (daily 1-hr maximum) and 
NO2 (24-hr average) to have β-values of 
8.39 × 10–4/ppb and 7.48 × 10–4/ppb, respec-
tively, based on (although not identical to) 
Burnett et al. (2004). We include NO2 in 
our analy sis for Canada based on the recom-
mendation of Brook et al. (2007) and because 
of its inclusion in the Canadian Air Quality 
Health Index (AQHI) (Stieb et al. 2008).
For the United States, we used results 
from different epidemiological studies, based 
in full or part on U.S. time-series data, to 
examine the importance of choice of met-
rics based on different averaging periods. 
Our default U.S. estimations are based on 
the widely used β-value of 5.2 × 10–4/ppb for 
24-hr average O3 from Bell et al. (2004), but 
we also consider a β-value of 3.9 × 10–4/ppb 
for daily 1-hr maximum O3 from Ito et al. 
(2005) for comparison. Our adjoint cost 
function for the United States includes only 
O3 because no commonly accepted associa-
tion between NO2 and short-term mortality 
is available for the United States.
Mortality valuation estimates driven by 
Equation 2 are a function of population demo-
graphics. For Canada, we used 2007 total 
population and annual non accidental baseline 
mortality rates (with no distinction by age 
category) for each of Canada’s census divisions 
from AQBAT. For the United States, total 
population and baseline mortality rates were 
obtained for each county from the Centers 
for Disease Control and Prevention (CDC). 
Nonaccidental mortality rates were calculated 
from International Classification of Disease 
(ICD)-10 (World Health Organization 1994) 
codes A–R as in Bell et al. (2004). We applied 
VSLs in 2011 equivalents (adjusted using the 
Consumer Price Index) of $5.7M CAD in 
Canada (from AQBAT) and $8.1M USD 
in the United States [U.S. Environmental 
Protection Agency (EPA) 2010]. When influ-
ences on the two countries were compared or 
added, exchange rate parity was assumed.
Through monetary valuation of mortality, 
we aimed to establish a bene fit–cost assess-
ment framework for streamlined comparison 
between societal bene fits and associated pollu-
tion abatement costs. We refer to our mortality 
count valuation as “health bene fits” hereafter 
for simplicity, while recognizing that our cal-
culated values represent a societal willingness to 
pay to reduce the risk of premature death. Our 
health bene fit estimations are overall conserva-
tive in that we are accounting for short-term 
mortality from gas-phase pollutants without 
including morbidity or long-term effects. Note 
that we refer to health bene fit influences of 
marginal source emission reductions when 
using the term “source attribution.”
Health bene fit estimation case study. We 
used the U.S. EPA’s Community Multiscale 
Air Quality (CMAQ) model (Byun and Schere 
2006) and its adjoint for health bene fit source 
attribution. The description and validation of 
the adjoint of CMAQ has been reported previ-
ously (Hakami et al. 2007). The current adjoint 
model for CMAQ only includes gas-phase pro-
cesses (chemistry and transport) of 72 active 
species. Our application of CMAQ was driven 
by meteorology from the Weather Research 
and Forecasting (WRF) model (Skamarock 
Pappin and Hakami
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et al. 2005) and emissions calculated on a day-
by-day, hour-by-hour basis using the Sparse 
Matrix Operator Kernel Emissions (SMOKE) 
model (University of North Carolina Institute 
for the Environment 2009). Emissions were 
projected to our simulation year from the 2005 
National Emissions Inventory (NEI) for the 
United States and the 2006 National Pollutant 
Release Inventory (NPRI) for Canada. Our 
simulation was conducted over a continen-
tal domain with a horizontal grid resolu-
tion of 36 km (i.e., a matrix of 36 × 36 km 
grid cells), 34 vertical layers extending into 
the stratosphere, and for the summer of 
2007. When compared to O3 observations, 
our simulations showed a 16.5% mean frac-
tional error (MFE) and +5.5% mean fractional 
bias (MFB) [see Supplemental Material, p. 3 
(http://dx.doi.org/10.1289/ehp.1205561)]. 
Therefore, our exposure metrics are fairly 
accurate but slightly over estimated; however, 
this bias in concentrations is not expected to 
have a significant impact on source attribution 
results. Without capturing source influences 
on exposure to PM (the adjoint of CMAQ 
for PM is still in development) or other short/
long-term effects, we regard our study as a 
proof-of-concept analy sis.
Results
We estimated Canadian and U.S. health 
bene fits from NOx and VOC emission reduc-
tions in each location or grid cell (i.e., each 
36 × 36 km box) (Figure 1). Estimated health 
bene fit influences are reported in $1,000s per 
day ($K/day) for a 10% change in emissions 
in all layers, and they represent daily contribu-
tions to annual health bene fits (i.e., baseline 
mortality is scaled to a daily rate). For exam-
ple, in Figure 1A, a value of $100,000/day in 
a grid cell indicates that a 10% reduction in 
NOx emissions from that cell would bene fit 
Canada by $100,000/day in reduced mor-
tality nation wide, whereas in Figure 1B, a 
value of $100,000/day in a grid cell indicates 
that a 10% reduction in NOx emissions from 
that cell would bene fit the United States by 
$100,000/day in reduced mortality nation-
wide. Note that the adjoint method provides 
source- specific information but lacks receptor 
specificity, and therefore, the distribution of 
bene fits across receptors (i.e., mortality reduc-
tions according to geographic location) cannot 
be seen in these results. However, the model 
does provide a means to quantify national-
level bene fits resulting from both domestic 
emission reductions and reductions in emis-
sions in the adjacent country. Health bene fits 
are average daily influences over 1 July 2007 
to 30 September 2007 and are reported in 
each country’s respective currency.
Attribution of Canadian health bene fits to 
North American sources. Canadian health bene-
fits from changes in exposure to both O3 (daily 
1-hr maximum) and NO2 as a consequence 
of reductions in NOx emissions are shown in 
Figure 1A. Most notable is the tendency of 
influences to exist in proximity to population 
centers in Canada, suggesting a strong local 
component to these health bene fits. Although 
emissions from sources in high-population 
urban areas will have a greater likelihood of 
influencing population exposure to O3 and 
NO2, their influence can be extended across 
the nations. Long-range influences of sources 
Figure 1. Average daily health bene fit influences of emissions from individual source locations for Canada (A,C) and the United States (B,D) estimated for a 10% 
reduction in anthropogenic emissions of NOx (A,B) and VOCs (C,D). Health bene fit influences on Canada account for both O3- and NO2-related mortality (A,C), 
whereas influences on the United States account for mortality associated with O3 exposure only (B,D). Health bene fits are average daily influences from 1 July to 
30 September 2007. Note that bene fits are shown according to the locations of the emissions sources that determine them, rather than the locations that experi-
ence the health bene fits. For example, influences of both U.S. and Canadian NOx sources shown in A indicate nation wide bene fits experienced by Canadians 
only, whereas influences of U.S. and Canadian NOx sources shown in B indicate nation wide bene fits experienced by Americans only.
NOx → Canada O3 + NO2
VOC → Canada O3 + NO2 VOC → United States O3
NOx → United States O3 
> 105.0
> 25.0
20.0
15.0
10.0
5.5
3.0
1.5
80.0
55.0
35.0
20.0
10.0
–5.0
–30.0
< –60.0
< 0.0
5.0
$K
/d
ay
$K
/d
ay
 > 25.0
20.0
15.0
10.0
5.5
3.0
1.5
 < 0.0
> 105.0
80.0
55.0
35.0
20.0
10.0
–5.0
–30.0
< –60.0
5.0
$K
/d
ay
$K
/d
ay
Source attribution of air quality health benefits
Environmental Health Perspectives • volume 121 | number 5 | May 2013 575
from locations in the United States on bene fits 
accrued in Canada reflect the relatively long 
atmospheric lifetime of O3, whereas influences 
on NO2 occur more locally [for bene fits related 
to O3 and NO2 separately, see Supplemental 
Material, Figure S1 (http://dx.doi.org/10.1289/
ehp.1205561)]. The largest overall influence 
came from emissions in Hamilton (upwind 
of Toronto, Ontario, Canada), reaching 
$253,000/day (Figure 1A). Significant influ-
ences were also seen from emissions in the 
Quebec City–Windsor Corridor and emis-
sions from the northeastern United States (e.g., 
$211,000/day in Montreal, Quebec, Canada 
and $47,000/day in Detroit, MI, USA). VOC 
emissions had significantly lower estimated 
influences on mortality (Figure 1C), with 
the largest bene fit seen for emission reduc-
tions upwind of the Greater Toronto Area 
($54,000/day for a 10% reduction) where a 
VOC-limited chemical regime exists on many 
summer days (i.e., production of O3 is more 
affected by VOC availability, rather than NOx 
concentrations). Canada-wide health bene fits 
have consistently positive sensitivities to anthro-
pogenic VOC emissions across the domain.
Attribution of U.S. health bene fits to North 
American sources. Health bene fit influences on 
the United States from anthropogenic NOx 
emissions are calculated for O3 exposure only 
(based on a 24-hr average metric; Figure 1B). 
In comparison to results for Canada, contri-
butions of North American NOx emissions 
toward U.S. mortality valuations are traced 
to sources dispersed over a wider geographic 
area and have generally higher magnitudes 
due to both the larger populations and the 
higher emissions in the United States. The 
largest estimated bene fits were from reduc-
tions in emissions from sources near Atlanta, 
Georgia ($181,000/day for a 10% reduction 
in NOx emissions); comparable to the influ-
ence seen from NOx emission reductions in 
Montreal in Figure 1A. We also estimated 
substantial negative sensitivities or dis bene fits 
from emissions originating in large U.S. cities 
(e.g., New York, NY, and Los Angeles, CA, at 
–$681,000/day and –$244,000/day, respec-
tively). These negative influences coincided 
with NOx-inhibited atmospheric conditions 
where O3 production increases as NOx avail-
ability decreases; thus reducing NOx emissions- 
increased O3-related mortality. This is in con-
trast with consistently positive bene fits esti-
mated for Canada (Figure 1A), where any 
disbene fits in O3-related mortality under 
NOx-inhibited conditions were offset by con-
comitant bene fits in NO2-related mortality. 
Our estimated bene fits for the United States 
(Figure 1B) do not account for NO2 exposure, 
and thus negative values persisted under NOx-
inhibited conditions. We also observed that 
estimated bene fits from reductions in VOC 
emissions (Figure 1D) were significantly higher 
in magnitude than for Canada, particularly for 
VOC-limited (or NOx-inhibited) metropoli-
tan regions (the largest influences are in New 
York and Los Angeles, at $294,000/day and 
$272,000/day for 10% reductions in VOC 
emissions in each city, respectively).
A few points about disbene fits from 
NOx emission reductions in large U.S. cities 
(Figure 2A) are worth mentioning. First, only 
O3-related mortality was included in our health 
bene fit estimates. If PM-related health effects 
were considered as well, these disbene fits would 
be expected to diminish because of reduced 
inorganic PM concentrations. Second, adjoint 
sensitivities provide a measure of individual 
source (or location) contributions that, if con-
sidered in isolation, should be regarded as local 
in nature. In reality, emission reductions are 
likely to be introduced within a larger regional 
and/or national context which may alter 
adjoint source influences, and in some cases 
may turn disbene fits into bene fits. Previous 
forward sensitivity studies have shown that 
influences of NOx emissions on O3 concentra-
tions remain linear up to about a 30% change 
in domain-wide NOx emissions (Hakami 
et al. 2004). Consequently, adjoint sensitiv-
ity estimates may not be valid over changes in 
emissions that are large enough to affect the 
chemical regime of the atmosphere. Therefore, 
Figure 2. Daily variability of influences from a 10% reduction in anthropogenic emissions of NOx originating 
from major cities on short-term mortality due to O3 exposure in Canada (and Detroit, MI, USA) (A) and the 
United States (B) in 2007. (C) Daily variability in NOx and VOC influences from Los Angeles on mortality in 
the United States. Influences are shown for single grid cells coinciding with the center of each city.
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in the presence of widespread and substantial 
changes in emissions, a multi step analy sis of 
health bene fits (i.e., multiple adjoint simula-
tions for gradually altered emission baselines 
over time) is more appropriate. Estimation of 
adjoint sensitivities along the emission control 
trajectory would result in gradually diminish-
ing disbene fits as changes in emissions become 
substantial enough to shift the predominant 
chemical regime in cities away from a NOx-
inhibited environment. Finally, the results 
shown in Figure 1 do not consider positive 
transboundary influences (e.g., the bene fits of 
reduced O3 exposure in Europe as a result of 
reducing U.S. NOx emissions).
Temporal variability in health bene fit 
influences. The dependence of atmospheric 
pollutant transformation and transport on 
meteorological conditions causes a great deal 
of day-to-day variability in health bene fit 
attributions. Figure 2 depicts time-variant 
influences of 10% reductions in NOx or VOC 
emissions from sources in select cities on 
Canada-wide and U.S.-wide mortality due to 
O3 exposure. Daily snapshots (i.e., the spatial 
distribution of influences on specific days) are 
shown in Supplemental Material, Figure S2 
(http://dx.doi.org/10.1289/ehp.1205561).
Significant day-to-day fluctuations in 
health bene fit influences were evident for 
emission sources in all cities. Reductions in 
emissions from sources in major Canadian cit-
ies (e.g., Toronto and Montreal; Figure 2A) 
resulted in some days with sizably negative 
influences on O3-related mortality in Canada 
(though increases in O3-related mortality were 
counteracted by decreases in NO2-related mor-
tality that are not shown in Figure 2). In the 
case of the United States, NOx emission reduc-
tions in New York and Los Angeles (Figure 2B) 
contributed, on average, large disbene fits to 
national O3 mortality. On the other hand, 
reductions in emissions from sources in or near 
Atlanta showed consistent bene fits on daily 
O3-related mortality due to the abundance of 
biogenic VOCs and a predominantly NOx-
limited chemical regime (such that O3 pro-
duction is always expected to decrease as NOx 
emissions are reduced). Furthermore, strongly 
NOx-inhibited urban cores such as Los Angeles 
exhibited an inversely correlated behavior 
between NOx and VOC influences on day-
to-day mortality because reductions in NOx 
will promote O3 production (and increase 
O3-related mortality) under these conditions, 
although reductions in VOCs on the same 
days will decrease O3 production and related 
mortality (Figure 2C).
The significant daily variability observed in 
health bene fit influences has important policy 
implications. Air quality decisions are under-
standably made based on the overall or average 
estimated impact of pollution control options. 
However, long-term measures taken based on 
average conditions may be effective on some 
days and ineffective on others. Significant day-
to-day variability in our estimates suggests that 
targeted short-term measures guided by health 
bene fit influences may complement long-term 
strategic planning for air quality improvement. 
Although air quality forecasting efforts have so 
far been focused on concentration predictions, 
forecasting health bene fit sensitivities for guid-
ing short-term emission modification seems to 
be the next logical step.
Discussion
Figure 1 provides basic aggregate influences on 
Canadian and U.S. health bene fits from vari-
ous anthropogenic sources in North America. 
We explore and discuss policy consequences 
of these results in more detail below.
Cross-border transport of health bene fits. 
To assess the impact of cross-border transport 
on national mortality, we summed health bene-
fit influences coming from emission sources 
within Canada and the United States separately 
for two scenarios: a) Canadian populations as 
the receptor for O3 and NO2 exposure, and 
b) U.S populations as the receptor for O3 expo-
sure. These summations should be regarded as 
marginal influences due to a modest decrease 
in emissions (i.e., 10%) rather than total con-
tributions (or apportionment) resulting from 
setting all emissions to zero and thus removing 
the total influence of each country. As before, 
we used VSL and epidemiological statistics 
consistent with the approaches taken and/or 
time-series studies done in each country.
For Canadian O3 and NO2 exposure, 
almost all of the long-range influences from 
U.S. emissions are due to O3. If all NOx 
sources in the United States reduced emissions 
by 10%, Canada would experience an average 
estimated bene fit of $3.8M/day (< 1 death/day 
at a VSL of $5.7M). Similarly, a 10% reduc-
tion in all Canadian NOx emissions would 
produce an average bene fit of $4.0M/day on 
Canadian health. For the exposure of the U.S. 
population to O3, cross-border transport of 
NOx resulting from a 10% reduction in emis-
sions from Canadian sources would result 
in an average bene fit to the United States of 
$1.7M/day, whereas the total influence of a 
10% reduction in U.S. emissions on American 
health bene fits is estimated to be $51.5M/day 
(~ 6 deaths/day at a VSL of $8.1M). In com-
parison with NOx, cross-border influences of 
VOC emissions on both Canadian and U.S. 
populations are substantially smaller and more 
local in nature.
The absolute magnitudes of cross-border 
mortality influences are comparable for the 
United States and Canada. However, even in 
the case of Canadian health bene fits, there is a 
significant domestic component. On specific 
days, cross-border transport of U.S. emissions 
may have a greater influence on Canadian 
mortality than domestic emissions [see exam-
ples in Supplemental Material, Figure S2 
(http://dx.doi.org/10.1289/ehp.1205561)], 
but in general, we estimate that significant 
bene fits would be gained from domestic emis-
sion controls in Canada. Also, an examination 
of influences by emission release layers shows 
that surface emissions (layer 1) are by far more 
influential than elevated sources (layers 2–8) 
(see Supplemental Material, Figure S3). This 
suggests that transportation emissions may be 
more influential on O3 (and NO2) mortality 
than industrial sources.
Effect of averaging period on health bene fit 
influences. In the results discussed so far here, 
we have used daily 1-hr maximum O3 expo-
sure metrics to estimate bene fits for Canada, 
and 24-hr average O3 exposure metrics to esti-
mate bene fits for the United States, as these 
are the common metrics used in each country. 
Daily average and 1-hr maximum O3 con-
centrations are often correlated, but would 
respond differently to emission reductions of 
O3 precursors. To explore the impact of the 
choice of metric on health bene fit estimates, 
we repeat our adjoint calculations for U.S. 
mortality based on a daily 1-hr maximum O3 
concentration response factor from Ito et al. 
(2005). Because Ito et al. (2005) and Bell et al. 
(2004) used different underlying data, our 
comparison should be regarded as qualita-
tive; we mainly aim to examine differences in 
 patterns and tendencies.
Health bene fit estimates based on the 1-hr 
exposure metric (Figure 3B) are consistently 
higher than estimates based on the 24-hr aver-
age metric (Figure 3A). More important, some 
locations that exhibit negative sensitivities 
(i.e., where emission reductions are associated 
with increased mortality) with the 24-hr aver-
aging period (e.g., around the Great Lakes) 
have sizable estimated bene fits based on a 
1-hr metric. This is expected because the daily 
exposure metric includes night time influences 
when NOx reductions are likely to result in 
increased O3 concentrations, resulting in nega-
tive influences on mortality. In contrast, NOx 
reductions during the day are more likely to 
have beneficial influences due to reductions 
in O3, except in urban environments that 
are extremely NOx-inhibited. In extremely 
NOx-rich urban cores such as New York or 
Los Angeles, NOx disbene fits persist (or can 
become more significant) even with exposure 
metrics based on 1-hr maximum concentra-
tions. Although we examined only 1-hr and 
24-hr metrics for the United States, these diur-
nal tendencies are an important consideration 
for the 8-hr O3 metric used in regulations.
Health bene fit influences of unit source 
reductions. Day-to-day and temporal aver-
age health bene fit influences are a function of 
a) population demographics, b) physical and 
chemical environmental processes that define 
Source attribution of air quality health benefits
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source-receptor relationships, and c) the mag-
nitude of emissions at each source location. 
In general, emissions of NOx or VOCs from 
a grid cell will have a relatively large influence 
if they are large in magnitude, or if there is a 
large population exposed to their emissions, 
or both. A grid cell near a populous area has a 
large potential for influencing human health, 
but if that location has very little actual emis-
sions, it will exert no influence on estimated 
bene fits. To remove the inherent dependency 
of sensitivities on the spatial and temporal dis-
tribution of emission quantities, we estimated 
health bene fit influences for hypothetical unit 
reductions in anthropogenic NOx and VOC 
emissions of 1 metric ton/year (Figure 4A,B). 
Unit reductions of NOx and VOC emis-
sions are spread evenly throughout all days 
of the year and are based on domain-wide 
diurnal emission patterns assigned to all grid 
cells equally. The resulting influences represent 
marginal, annual bene fits (extrapolated from 
summer months to the full year) from unit 
emission reductions at each location, which 
Figure 3. Average daily influences on U.S. short-term mortality estimated for various averaging periods from a 10% reduction in anthropogenic emissions of NOx. 
Health bene fit influences are calculated based on 24-hr average O3 concentrations (A, as in Figure 1B) and daily 1-hr maximum O3 concentrations (B).
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can be invaluable decision-making parameters. 
The results depict the overall influence of the 
same reduction in each source on both Canada 
(O3 and NO2) and the United States (O3).
These estimated health bene fit influ-
ences have significantly greater spatial cover-
age than the estimates shown in Figure 1. 
Health bene fit influences mainly reflect bene-
fits from NOx reductions, and are highest 
along the Quebec City–Windsor Corridor 
(Canada) and in California (USA), con-
sistent with the fact that adjoint forcing is 
driven by downwind populations (largest val-
ues of approximately $75,000/year in Santa 
Barbara, Simi Valley, and west of Montreal, 
Dorval). As expected, large cities have lower 
attributed bene fits (due to a VOC-limited 
chemical regime resulting in increased O3 
concentrations and O3-related mortality with 
reductions in NOx). Estimates in Canada are 
generally larger because they include influ-
ences on both O3 and NO2 exposure.
Using fleet-average emission rates, values 
in Figure 4A and B can be translated into a 
bene fit attribution map for personal vehicle 
use (Figure 4C). Values in Figure 4C can be 
interpreted as the yearly bene fit of removing 
one average vehicle from the road in each 
grid cell, due to elimination of the vehicle’s 
NOx and VOC emissions. Yearly bene fits are 
calculated using annual per-vehicle emission 
rates of 0.010 metric ton/year for NOx and 
0.014 metric ton/year for VOCs as averages 
taken from the mobile emission inventory 
developed by SMOKE. Some major urban 
areas in the United States show small esti-
mated influences from transportation (e.g., 
Los Angeles $0/year), with significant disbene-
fits estimated for New York (–$750/year), 
Boston (–$150/year), and a few other cities. 
In Canada, because of the inclusion of NO2 
in the adjoint cost function, no disbene fits 
are observed and estimated urban bene fits are 
substantial, with the largest Canadian influ-
ences in Montreal ($770/year), Mississauga, 
Ontario, Canada ($440/year), and Vancouver, 
British Columbia, Canada, ($450/year). In 
the United States, influences from the Pacific 
Ocean Highway in regions other than Los 
Angeles and the Bay Area are substantial, 
ranging between $300/year and $830/year.
Conclusions
We used the adjoint of CMAQ to estimate 
nation wide health bene fits from reduced O3- 
and NO2-related short-term mortality result-
ing from NOx and VOC emission reductions 
in each source location. Our modeling period 
represents a single O3 season in 2007, and 
does not capture inter-annual variability in 
health bene fit influences. Furthermore, while 
our calculations based on summer months are 
likely to overestimate annual bene fits when 
extrapolated to the full year, we believe that, 
overall, we under estimate health bene fits in 
not accounting for morbidity and long-term 
or PM-related mortality.
Our estimates are affected by various 
uncertainties in epidemiological values, mor-
tality valuation, emissions characterization, 
and atmospheric modeling (e.g., represen-
tation of complex atmospheric chemistry). 
Emission uncertainties are of particular impor-
tance because they are thought to be the major 
source of uncertainty in simulated concentra-
tions (Russell and Dennis 2000). Sharp spatial 
gradients of health bene fit influences can only 
be captured with higher resolution simulations 
(i.e., a smaller grid cell size). Although these 
results provide insight into the general behav-
ior of health bene fit attributions, they should 
be regarded as a proof-of-concept demonstra-
tion of the adjoint method’s capability to 
delineate health bene fit influences. More con-
clusive quantification of influences requires 
further research with high-resolution, multi-
year, multi pollutant simulations that span all 
possible health outcomes with adequate con-
sideration for uncertainties.
Our results indicate important tendencies 
of health bene fit influences:
From the day-to-day variability in health •	
bene fit influences, we infer that the efficacy 
of long-term pollution reduction measures 
could vary greatly in the short term.
We note a sizeable influence of cross- border •	
transport, with the estimated influence of 
U.S. emissions on Canada being larger than 
the estimated influence of Canadian emis-
sions on the United States, but comparable 
in magnitude to the influence of domestic 
Canadian emissions on Canadian health. 
From a Canadian perspective, although the 
tendency to blame poor air quality on emis-
sions in the United States seems somewhat 
justified, there is significant bene fit to be 
gained from domestic emission controls.
Our results point to substantial differences •	
in the response of exposure metrics to con-
trol of emissions when calculated for various 
averaging periods. These differences could 
have important regulatory implications and 
as such, this topic requires further investi-
gation (with inclusion of the 8-hr metric) 
based on consistent under lying epidemio-
logic models.
Our estimates suggest that ground-level •	
sources have the largest influences except 
where significant industrial activity exists. As 
such, we anticipate a potentially important 
application of this approach in transporta-
tion planning. For example, based on our 
results, we estimate health bene fits of the 
subway system in Toronto to be approxi-
mately $130M/year from reduced short-term 
O3 and NO2-related mortality only.
Most important, our results suggest that •	
potential health bene fits are substantial and 
possibly under represented in the current 
bene fit–cost analy sis frameworks that lack 
source specificity. For example, the U.S. 
market-based permit price (the average 
marginal abatement cost) available to power 
plants for 1 metric ton of NOx emissions 
reduction during the O3 season in 2007 was 
approximately $900 (U.S. EPA 2008). By 
contrast, our corresponding estimated seventh 
layer (typical effective height for a power 
plant plume release) health bene fit influence 
for the Ohio River Valley is approximately 
$11,000/year. Such disparity between 
marginal abatement costs and marginal bene-
fits can be best addressed using the source-
 specificity offered by the adjoint approach.
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